Cargando…

2349 The role of interleukin-23 in human melanoma

OBJECTIVES/SPECIFIC AIMS: Interleukin-23 (IL-23) promotes differentiation of naïve T-cells into Th17 cells, which drive the pathogenesis of autoinflammatory conditions such as psoriasis. IL-23-neutralizing antibody therapies are now in use for treatment of psoriasis, with promising results. Studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Jani, Aditi, Chaudhary, Sandeep, Janjetovic, Zorica, Sherwani, Mohammad A., Yusuf, Nabiha, Slominski, Andrzej, Athar, Mohammad, Elmets, Craig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798532/
http://dx.doi.org/10.1017/cts.2018.135
_version_ 1783460068303306752
author Jani, Aditi
Chaudhary, Sandeep
Janjetovic, Zorica
Sherwani, Mohammad A.
Yusuf, Nabiha
Slominski, Andrzej
Athar, Mohammad
Elmets, Craig
author_facet Jani, Aditi
Chaudhary, Sandeep
Janjetovic, Zorica
Sherwani, Mohammad A.
Yusuf, Nabiha
Slominski, Andrzej
Athar, Mohammad
Elmets, Craig
author_sort Jani, Aditi
collection PubMed
description OBJECTIVES/SPECIFIC AIMS: Interleukin-23 (IL-23) promotes differentiation of naïve T-cells into Th17 cells, which drive the pathogenesis of autoinflammatory conditions such as psoriasis. IL-23-neutralizing antibody therapies are now in use for treatment of psoriasis, with promising results. Studies in mice have shown that IL-23 plays a role in inhibiting the growth, progression, and metastasis of melanomas. Thus, therapeutic neutralization of IL-23 in patients may inadvertently increase their susceptibility to development of melanoma. In this study, we aim to characterize expression of IL-23 receptors (IL-23R) in human melanocytes and melanoma cells and tissue and to study the effect of IL-23 on growth, proliferation, and tumorigenicity of these cells. METHODS/STUDY POPULATION: IL-23R expression was characterized using immunofluorescence staining, Western blot, and flow cytometric analysis. Response of melanoma and melanocytes to recombinant IL-23 treatment will be studied through similar methods in addition to assays of cell proliferation and tumorigenicity. RESULTS/ANTICIPATED RESULTS: Preliminary immunofluorescence staining and flow cytometry results indicate that both human melanoma and primary melanocytes express IL-23 receptors. Western blot analysis showed that melanoma cell line A375 expressed nearly twice the amount of IL-23R versus normal melanocytes (p<0.05). Based on previous studies, we anticipate that addition of recombinant IL-23 to cultures of melanoma will reduce proliferative potential, and we expect similar addition to normal melanocytes will increase DNA repair mechanisms. DISCUSSION/SIGNIFICANCE OF IMPACT: In showing that human melanocytes and melanoma cells express IL-23 receptors, and potentially showing the inhibitory effect of IL-23 in the development of melanocytic neoplasms, our findings imply that using IL-23 neutralizing therapies may increase risk of developing melanoma, especially in patients who are already susceptible. As such, these therapies must be used with great care in these patients.
format Online
Article
Text
id pubmed-6798532
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-67985322019-10-28 2349 The role of interleukin-23 in human melanoma Jani, Aditi Chaudhary, Sandeep Janjetovic, Zorica Sherwani, Mohammad A. Yusuf, Nabiha Slominski, Andrzej Athar, Mohammad Elmets, Craig J Clin Transl Sci Basic/Translational Science/Team Science OBJECTIVES/SPECIFIC AIMS: Interleukin-23 (IL-23) promotes differentiation of naïve T-cells into Th17 cells, which drive the pathogenesis of autoinflammatory conditions such as psoriasis. IL-23-neutralizing antibody therapies are now in use for treatment of psoriasis, with promising results. Studies in mice have shown that IL-23 plays a role in inhibiting the growth, progression, and metastasis of melanomas. Thus, therapeutic neutralization of IL-23 in patients may inadvertently increase their susceptibility to development of melanoma. In this study, we aim to characterize expression of IL-23 receptors (IL-23R) in human melanocytes and melanoma cells and tissue and to study the effect of IL-23 on growth, proliferation, and tumorigenicity of these cells. METHODS/STUDY POPULATION: IL-23R expression was characterized using immunofluorescence staining, Western blot, and flow cytometric analysis. Response of melanoma and melanocytes to recombinant IL-23 treatment will be studied through similar methods in addition to assays of cell proliferation and tumorigenicity. RESULTS/ANTICIPATED RESULTS: Preliminary immunofluorescence staining and flow cytometry results indicate that both human melanoma and primary melanocytes express IL-23 receptors. Western blot analysis showed that melanoma cell line A375 expressed nearly twice the amount of IL-23R versus normal melanocytes (p<0.05). Based on previous studies, we anticipate that addition of recombinant IL-23 to cultures of melanoma will reduce proliferative potential, and we expect similar addition to normal melanocytes will increase DNA repair mechanisms. DISCUSSION/SIGNIFICANCE OF IMPACT: In showing that human melanocytes and melanoma cells express IL-23 receptors, and potentially showing the inhibitory effect of IL-23 in the development of melanocytic neoplasms, our findings imply that using IL-23 neutralizing therapies may increase risk of developing melanoma, especially in patients who are already susceptible. As such, these therapies must be used with great care in these patients. Cambridge University Press 2018-11-21 /pmc/articles/PMC6798532/ http://dx.doi.org/10.1017/cts.2018.135 Text en © The Association for Clinical and Translational Science 2018 http://creativecommons.org/licenses/by/4.0/ This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Basic/Translational Science/Team Science
Jani, Aditi
Chaudhary, Sandeep
Janjetovic, Zorica
Sherwani, Mohammad A.
Yusuf, Nabiha
Slominski, Andrzej
Athar, Mohammad
Elmets, Craig
2349 The role of interleukin-23 in human melanoma
title 2349 The role of interleukin-23 in human melanoma
title_full 2349 The role of interleukin-23 in human melanoma
title_fullStr 2349 The role of interleukin-23 in human melanoma
title_full_unstemmed 2349 The role of interleukin-23 in human melanoma
title_short 2349 The role of interleukin-23 in human melanoma
title_sort 2349 the role of interleukin-23 in human melanoma
topic Basic/Translational Science/Team Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798532/
http://dx.doi.org/10.1017/cts.2018.135
work_keys_str_mv AT janiaditi 2349theroleofinterleukin23inhumanmelanoma
AT chaudharysandeep 2349theroleofinterleukin23inhumanmelanoma
AT janjetoviczorica 2349theroleofinterleukin23inhumanmelanoma
AT sherwanimohammada 2349theroleofinterleukin23inhumanmelanoma
AT yusufnabiha 2349theroleofinterleukin23inhumanmelanoma
AT slominskiandrzej 2349theroleofinterleukin23inhumanmelanoma
AT atharmohammad 2349theroleofinterleukin23inhumanmelanoma
AT elmetscraig 2349theroleofinterleukin23inhumanmelanoma